CA3200779A1 - Composition non micronisee de bilastine - Google Patents

Composition non micronisee de bilastine

Info

Publication number
CA3200779A1
CA3200779A1 CA3200779A CA3200779A CA3200779A1 CA 3200779 A1 CA3200779 A1 CA 3200779A1 CA 3200779 A CA3200779 A CA 3200779A CA 3200779 A CA3200779 A CA 3200779A CA 3200779 A1 CA3200779 A1 CA 3200779A1
Authority
CA
Canada
Prior art keywords
composition
weight
bilastine
pyrrolidone
based polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3200779A
Other languages
English (en)
Inventor
Strusi ORAZIO LUCA
Jose Vicente Hernandez Ballester
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Disproquima Sa
Noucor Health SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3200779A1 publication Critical patent/CA3200779A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition comprenant une quantité thérapeutiquement efficace de bilastine ayant une distribution des tailles de particules D90 de 15 à 90 µm mesurée par diffraction laser ; et un polymère à base de pyrrolidone ; conjointement à un excipient ou support pharmaceutiquement acceptable ou plus ; et un procédé pour sa préparation. Elle concerne également l?utilisation de la composition dans le traitement de processus pathologiques à médiation par l?histamine et des réactions allergiques.
CA3200779A 2020-12-23 2021-12-02 Composition non micronisee de bilastine Pending CA3200779A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20383149 2020-12-23
EP20383149.0 2020-12-23
PCT/EP2021/083930 WO2022135863A1 (fr) 2020-12-23 2021-12-02 Composition non micronisée de bilastine

Publications (1)

Publication Number Publication Date
CA3200779A1 true CA3200779A1 (fr) 2022-06-30

Family

ID=74194484

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3200779A Pending CA3200779A1 (fr) 2020-12-23 2021-12-02 Composition non micronisee de bilastine

Country Status (3)

Country Link
EP (1) EP4267109A1 (fr)
CA (1) CA3200779A1 (fr)
WO (1) WO2022135863A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026010576A1 (fr) * 2024-07-01 2026-01-08 Humanis Sağlik A.Ş. Composition pharmaceutique solide comprenant de la bilastine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2124167B1 (es) 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
NZ536551A (en) 2002-04-19 2006-08-31 Faes Farma S Preparation of polymorphous cyrstalline form, known as bilastine, and its antihistaminic and antiallergenic use
CN103356616A (zh) * 2013-06-29 2013-10-23 北京万全德众医药生物技术有限公司 一种含有比拉斯汀的药物组合物及其制备方法
CN106606486A (zh) * 2015-10-22 2017-05-03 天津市汉康医药生物技术有限公司 一种比拉斯汀片及其制备方法
EP3470062B1 (fr) * 2017-12-18 2020-10-28 Alfred E. Tiefenbacher (GmbH & Co. KG) Composition de comprimé pharmaceutique comprenant de la bilastine polymorphe forme 3 et de l'aluminométasilicate de magnésium

Also Published As

Publication number Publication date
EP4267109A1 (fr) 2023-11-01
WO2022135863A1 (fr) 2022-06-30

Similar Documents

Publication Publication Date Title
CA2726472C (fr) Formulations pharmaceutiques solides comprenant du bibw 2992
JP6041919B2 (ja) ８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩を含む錠剤処方物およびそれから作製される錠剤
JP2018184410A (ja) 非晶質ダパグリフロジンを含有する製剤
RU2713428C1 (ru) Частицы, содержащие аморфный эмпаглифлозин, способ их получения и содержащий их лекарственный препарат
TWI905371B (zh) 藥物組成物
WO2012085284A2 (fr) Formulations pharmaceutiques à charge médicamenteuse élevée comprenant de la dronédarone et des sels pharmaceutiquement acceptables de celles-ci
CA3200779A1 (fr) Composition non micronisee de bilastine
AU2018246258B2 (en) Pharmaceutical formulation
WO2009008004A2 (fr) Formulations à libération prolongée de divalproex de sodium
JP7682847B2 (ja) 医薬調製物
KR20210024593A (ko) 도파민-β-히드록실라제 억제제를 포함하는 제제 및 이의 제조 방법
JP7854233B2 (ja) アピキサバン含有組成物、アピキサバン含有固形製剤、及びアピキサバン含有固形製剤の製造方法
WO2014140159A1 (fr) Forme dosifiée comprenant du crizotinib
EP3072528B1 (fr) Composition comprenant un copolymère cationique et du vemurafenib basé sur des méthacrylates
EP4499039B1 (fr) Composition à libération prolongée solide comprenant des antagonistes du récepteur b2 de la bradykinine
US20250268887A1 (en) Therapeutic uses of bradykinin b2-receptor antagonists
JP2026068686A (ja) アピキサバン含有組成物、アピキサバン含有固形製剤、及びアピキサバン含有固形製剤の製造方法
WO2023227997A1 (fr) Composition pharmaceutique contenant une combinaison d'azilsartan et de chlorthalidone et son procédé de préparation
WO2026019402A1 (fr) Composition pharmaceutique comprenant une nanosuspension de canagliflozine
EA052832B1 (ru) Твердая композиция с пролонгированным высвобождением, содержащая антагонисты брадикининовых в2-рецепторов

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241122

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241122

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241122

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251126

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251126

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251201

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251201

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260122

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260122

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260122

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260122

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260122